Literature DB >> 20943985

Fitness disadvantage of transitional intermediates contributes to dynamic change in the infecting-virus population during coreceptor switch in R5 simian/human immunodeficiency virus-infected macaques.

Madina Shakirzyanova1, Wuze Ren, Ke Zhuang, Silvana Tasca, Cecilia Cheng-Mayer.   

Abstract

Fitness disadvantage of the transitional intermediates compared to the initial R5 viruses has been suggested to constitute one of the blockades to coreceptor switching, explaining the late appearance of X4 viruses. Using a simian model for human immunodeficiency virus type 1 (HIV-1) coreceptor switching, we demonstrate in this study that similar molecular evolutionary pathways to coreceptor switch occur in more than one R5 simian/human immunodeficiency virus (SHIV)(SF162P3N)-infected macaque. In infected animals where multiple pathways for expansion or switch to CXCR4 coexist, fitness of the transitional intermediates in coreceptor usage efficiency influences their outgrowth and representation in the infecting virus population. Dualtropic and X4 viruses appear at different disease stages, but they have lower entry efficiency than the coexisting R5 strains, which may explain why they do not outcompete the R5 viruses. Similar observations were made in two infected macaques with coreceptor switch, providing in vivo evidence that fitness disadvantage is an obstacle to X4 emergence and expansion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943985      PMCID: PMC3004298          DOI: 10.1128/JVI.01478-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.

Authors:  R Wyatt; M Thali; S Tilley; A Pinter; M Posner; D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

4.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

5.  Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype.

Authors:  C L Kuiken; J J de Jong; E Baan; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

6.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

Authors:  J Embretson; M Zupancic; J L Ribas; A Burke; P Racz; K Tenner-Racz; A T Haase
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

7.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.

Authors:  R Wyatt; N Sullivan; M Thali; H Repke; D Ho; J Robinson; M Posner; J Sodroski
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

9.  Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.

Authors:  S H Chiou; E O Freed; A T Panganiban; W R Kenealy
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

10.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

View more
  11 in total

1.  Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N.

Authors:  Madina Shakirzyanova; Lily Tsai; Wuze Ren; Agegneu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

2.  Accumulated mutations by 6 months of infection collectively render transmitted/founder HIV-1 significantly less fit.

Authors:  Chu Wang; Donglai Liu; Tao Zuo; Bhavna Hora; Fangping Cai; Haitao Ding; John Kappes; Christina Ochsenbauer; Wei Kong; Xianghui Yu; Tanmoy Bhattacharya; Alan S Perelson; Feng Gao
Journal:  J Infect       Date:  2019-12-05       Impact factor: 6.072

3.  Emergence of CD4 independence envelopes and astrocyte infection in R5 simian-human immunodeficiency virus model of encephalitis.

Authors:  Ke Zhuang; Ana Rachel Leda; Lily Tsai; Heather Knight; Carole Harbison; Agegnehu Gettie; James Blanchard; Susan Westmoreland; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

4.  Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.

Authors:  Wuze Ren; Alexandra Mumbauer; Agegnehu Gettie; Michael S Seaman; Kasi Russell-Lodrigue; James Blanchard; Susan Westmoreland; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2013-03-20       Impact factor: 5.103

5.  Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.

Authors:  Ke Zhuang; Andres Finzi; Jonathan Toma; Arne Frantzell; Wei Huang; Joseph Sodroski; Cecilia Cheng-Mayer
Journal:  Retrovirology       Date:  2012-12-13       Impact factor: 4.602

6.  Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.

Authors:  Ke Zhuang; Andres Finzi; Silvana Tasca; Madina Shakirzyanova; Heather Knight; Susan Westmoreland; Joseph Sodroski; Cecilia Cheng-Mayer
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

Review 7.  Coreceptor use in nonhuman primate models of HIV infection.

Authors:  Silvana Tasca Sina; Wuze Ren; Cecilia Cheng-Mayer
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

8.  Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome.

Authors:  Hongshuo Song; Jeffrey W Pavlicek; Fangping Cai; Tanmoy Bhattacharya; Hui Li; Shilpa S Iyer; Katharine J Bar; Julie M Decker; Nilu Goonetilleke; Michael K P Liu; Anna Berg; Bhavna Hora; Mark S Drinker; Josh Eudailey; Joy Pickeral; M Anthony Moody; Guido Ferrari; Andrew McMichael; Alan S Perelson; George M Shaw; Beatrice H Hahn; Barton F Haynes; Feng Gao
Journal:  Retrovirology       Date:  2012-10-30       Impact factor: 4.602

9.  Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques.

Authors:  Wuze Ren; Alexandra Mumbauer; Ke Zhuang; Carole Harbison; Heather Knight; Susan Westmoreland; Agegnehu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  Retrovirology       Date:  2013-01-31       Impact factor: 4.602

10.  Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.

Authors:  Borislav Savkovic; Geoff Symonds; John M Murray
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.